 <h1>Itraconazole Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of itraconazole include:</b> nausea. <b>Other side effects include:</b> vomiting.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to itraconazole: oral capsule, oral solution, oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of congestive heart failure occur during administration of itraconazole capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen.Drug Interactions: Coadministration of the following drugs are contraindicated with itraconazole capsules: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor. In addition, coadministration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia.</p><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Warning: Congestive Heart Failure and Drug InteractionsTolsura(TM)Congestive Heart Failure:Itraconazole can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. If signs or symptoms of congestive heart failure occur or worsen during administration of itraconazole, reassess the benefit and risk of continuing treatment.Drug Interactions:Coadministration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with itraconazole because plasma concentrations of such drugs are increased, which may also increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs.Coadministration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors.Increased plasma concentrations of some of these drugs can lead to QT prolongation and/or ventricular tachyarrhythmias, including occurrences of torsades de pointes, a potentially fatal arrhythmia.</p><p class="blackboxWarning-title">Oral route (Solution)</p><p>Congestive Heart Failure, Cardiac Effects and Drug Interactions: If signs or symptoms of congestive heart failure occur during administration of itraconazole oral solution, continued itraconazole use should be reassessed. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen.Drug Interactions: Coadministration of the following drugs are contraindicated with itraconazole oral solution: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor. In addition, coadministration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia.</p><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Do not use itraconazole to treat onychomycosis in patients with ventricular dysfunction (eg, congestive heart failure). If signs or symptoms of congestive heart failure occur, continued use should be reassessed. Itraconazole is contraindicated in patients concomitantly taking cisapride, pimozide, quinidine, dofetilide, levacetylmethadol (levomethadyl), felodipine, oral midazolam, nisoldipine, triazolam, lovastatin, simvastatin, ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine), or methadone. Concomitant administration can cause the plasma levels of the concomitant drug to increase. Serious cardiovascular events have been reported in patients taking cisapride, pimozide, levacetylmethadol (levomethadyl), methadone, or quinidine concomitantly with itraconazole or other CYP3A4 inhibitors.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, itraconazole may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking itraconazole:</p><p>
<i>More common</i>
</p><ul>
<li>Decreased urine output</li>
<li>dry mouth</li>
<li>fever</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>nausea</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>seizures</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>chest pain</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>cloudy urine</li>
<li>cold sweats</li>
<li>confusion</li>
<li>cough</li>
<li>dark urine</li>
<li>decrease in urine-concentrating ability</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>drowsiness</li>
<li>feeling unusually cold</li>
<li>headache</li>
<li>itching, skin rash</li>
<li>light-colored stools</li>
<li>mental changes</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>muscle spasms (tetany) or twitching</li>
<li>nervousness</li>
<li>noisy, rattling breathing</li>
<li>numbness and tingling around the mouth or fingertips</li>
<li>pounding in the ears</li>
<li>shivering</li>
<li>slow, fast, or pounding heartbeat or pulse</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stomach cramps or pain</li>
<li>sweating</li>
<li>swelling of the fingers, hands, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>trembling</li>
<li>troubled breathing at rest</li>
<li>unpleasant breath odor</li>
<li>vomiting of blood</li>
<li>weight gain</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blood in the urine or stools</li>
<li>blue lips and fingernails</li>
<li>burning, crawling, itching, numbness, painful, prickling, "pins and needles", or tingling feelings</li>
<li>continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>coughing that sometimes produces a pink frothy sputum</li>
<li>cracks in the skin</li>
<li>decreased appetite</li>
<li>difficulty with swallowing</li>
<li>dilated neck veins</li>
<li>disturbed color perception</li>
<li>double vision</li>
<li>extreme tiredness or weakness</li>
<li>fast or irregular breathing</li>
<li>feeling of discomfort</li>
<li>general feeling of tiredness or weakness</li>
<li>halos around lights</li>
<li>hearing loss</li>
<li>hives or welts</li>
<li>inflammation of the joints</li>
<li>joint pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>loss of heat from the body</li>
<li>loss of vision</li>
<li>lower back or side pain</li>
<li>night blindness</li>
<li>overbright appearance of lights</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid weight gain</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>red, swollen skin</li>
<li>scaly skin</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>stomach pain, continuing</li>
<li>stomach tenderness</li>
<li>swollen lymph glands</li>
<li>tunnel vision</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual weight gain or loss</li>
<li>upper right abdominal or stomach pain</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bloating</li>
<li>constipation</li>
<li>difficult, fast, noisy breathing</li>
<li>indigestion</li>
<li>loss of bladder control</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of itraconazole may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Decreased interest in sexual intercourse</li>
<li>difficulty having a bowel movement</li>
<li>difficulty with moving</li>
<li>discouragement</li>
<li>feeling of constant movement of self or surroundings</li>
<li>feeling sad or empty</li>
<li>inability to have or keep an erection</li>
<li>irritability</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>loss of interest or pleasure</li>
<li>muscle aching or stiffness</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>passing of gas</li>
<li>sensation of spinning</li>
<li>sleepiness or unusual drowsiness</li>
<li>soreness of the skin</li>
<li>stomach fullness or discomfort</li>
<li>stuffy or runny nose</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Belching</li>
<li>change in taste</li>
<li>hair loss or thinning of the hair</li>
<li>heartburn</li>
<li>increased need to urinate</li>
<li>increased sensitivity of the eyes or skin to sunlight</li>
<li>loss of taste</li>
<li>menstrual changes</li>
<li>passing urine more often</li>
<li>redness or other discoloration of the skin</li>
<li>severe sunburn</li>
</ul><p>
<!-- end oral capsule, oral solution, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to itraconazole: compounding powder, intravenous kit, oral capsule, oral solution, oral tablet</i></p><h3>General</h3><p>In clinical trials, side effects were reported in about 7% to 9% of patients receiving short-term therapy and about 15% of patients receiving prolonged (about 1 month) continuous therapy.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 11%), diarrhea (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Vomiting, abdominal pain or discomfort, dyspepsia, flatulence, gingivitis, constipation, ulcerative stomatitis, gastritis, gastroenteritis</p>
<p><b>Rare</b> (less than 0.1%): Pancreatitis</p>
<p><b>Frequency not reported</b>: Dysphagia, hemorrhoids, gastrointestinal disorder<sup>[Ref]</sup></p><p>Pancreatitis, abdominal pain, vomiting, dyspepsia, nausea, diarrhea, and constipation have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypertriglyceridemia (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Hypokalemia, increased blood alkaline phosphatase, hypomagnesemia, increased blood lactate dehydrogenase, hypophosphatemia, increased appetite</p>
<p><b>Uncommon</b> (0.1% to 1%): Fluid overload, hypocalcemia, anorexia, hyperglycemia</p>
<p><b>Frequency not reported</b>: Dehydration, decreased weight, hyperkalemia<sup>[Ref]</sup></p><p>Hypertriglyceridemia and hypokalemia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, hypoacusis, tremor, dysgeusia</p>
<p><b>Uncommon</b> (0.1% to 1%): Vertigo, somnolence, hypoesthesia, transient or permanent hearing loss, peripheral neuropathy</p>
<p><b>Rare</b> (less than 0.1%): Paresthesia, tinnitus<sup>[Ref]</sup></p><p>Peripheral neuropathy, paresthesia, hypoesthesia, headache, dizziness, tinnitus, transient or permanent hearing loss, dysgeusia, and tremor have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Rhinitis, upper respiratory tract infection, sinusitis, cough, pneumonia, increased sputum, dyspnea, pharyngitis, pulmonary infiltration</p>
<p><b>Uncommon</b> (0.1% to 1%): Pulmonary edema, pharyngolaryngeal pain</p>
<p><b>Frequency not reported</b>: Dysphonia<sup>[Ref]</sup></p><p>Pulmonary edema and dyspnea have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Other</h3><p>Edema and pyrexia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Pyrexia, injury, edema, chest pain, fatigue, malaise, pain, asthenia, Pneumocystis carinii infection, herpes zoster</p>
<p><b>Frequency not reported</b>: Unspecified infection, rigors, back pain, hot flushes, implantation complication, face edema, chills, generalized edema</p>
<p><b>Postmarketing reports</b>: Peripheral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus, hyperhidrosis, unspecified skin disorder, erythematous rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p><b>Rare</b> (less than 0.1%): Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, leukocytoclastic vasculitis, erythema multiforme, photosensitivity, alopecia<sup>[Ref]</sup></p><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, leukocytoclastic vasculitis, alopecia, photosensitivity, rash, pruritus, and urticaria have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Mild, transient elevations in liver function tests have occurred in 1% to 7% of patients receiving continuous therapy.</p>
<p></p>
<p>Serious hepatotoxicity (including some cases of fatal acute liver failure), hepatitis, and reversible increases in hepatic enzymes have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased hepatic enzymes (including reversible increases), bilirubinemia, abnormal liver function, increased ALT, jaundice, increased AST, increased GGT, hepatitis, hyperbilirubinemia</p>
<p><b>Rare</b> (less than 0.1%): Serious hepatotoxicity (including some cases of fatal acute liver failure)</p>
<p><b>Frequency not reported</b>: Cholestasis, cholestatic jaundice, hepatic failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, vein disorder, abnormal electrocardiogram</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypotension, orthostatic hypotension, vasculitis, sinus bradycardia, tachycardia</p>
<p><b>Rare</b> (less than 0.1%): Congestive heart failure</p>
<p><b>Frequency not reported</b>: Premature ventricular contractions, cardiac failure, left ventricular failure<sup>[Ref]</sup></p><p>Congestive heart failure has also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased serum creatinine</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal renal function, increased blood urea</p>
<p><b>Frequency not reported</b>: Renal impairment<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, anxiety, abnormal dreaming</p>
<p><b>Frequency not reported</b>: Insomnia, decreased libido, visual hallucinations, confusional state<sup>[Ref]</sup></p><p>An elderly patient experienced visual hallucinations, confusion, and weakness after receiving itraconazole.  The symptoms reappeared following accidental itraconazole doses 7 and 10 days later.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Pollakiuria, menstrual disorders, and erectile dysfunction have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Cystitis, urinary tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Impotence, menstrual disorders, abnormal urine analysis</p>
<p><b>Rare</b> (less than 0.1%): Pollakiuria, erectile dysfunction</p>
<p><b>Frequency not reported</b>: Albuminuria, hematuria, gynecomastia, male breast pain, bacteriuria</p>
<p><b>Postmarketing reports</b>: Urinary incontinence<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia, bursitis, back pain</p>
<p><b>Rare</b> (less than 0.1%): Increased blood creatine phosphokinase</p>
<p><b>Postmarketing reports</b>: Arthralgia<sup>[Ref]</sup></p><p>Increased blood creatine phosphokinase and myalgia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Local</h3><p>IV:</p>
<p><b>Common</b> (1% to 10%): Application site reaction</p>
<p><b>Frequency not reported</b>: Injection site inflammation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>At least 1 case of anaphylactic shock after long-term IV therapy has been reported.</p>
<p></p>
<p>Anaphylactic reactions, allergic reactions, serum sickness, and angioneurotic edema have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Rare</b> (less than 0.1%): Allergic reactions (e.g., pruritus, rash, urticaria, angioedema), serum sickness, angioneurotic edema, anaphylactic reaction</p>
<p><b>Frequency not reported</b>: Anaphylactic shock</p>
<p><b>Postmarketing reports</b>: Anaphylaxis, anaphylactoid reaction<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Visual disturbances (including blurred vision, diplopia)</p>
<p><b>Frequency not reported</b>: Abnormal vision<sup>[Ref]</sup></p><p>Visual disturbances (including blurred vision, diplopia) have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Leukopenia has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Rare</b> (less than 0.1%): Leukopenia</p>
<p><b>Frequency not reported</b>: Granulocytopenia</p>
<p><b>Postmarketing reports</b>: Neutropenia, thrombocytopenia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Adrenal insufficiency<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Sporanox injection (itraconazole)" Ortho Biotech Inc, Raritan, NJ. </p><p id="ref_2">2. Haria M, Bryson HM, Goa KL "Itraconazole: a review of its pharmacological properties and therapeutic use in the management of superficial fungal infections." Drugs 52 (1996): 253</p><p id="ref_3">3. Kim JA, Ahn KJ, Kim JM, Youn JI "Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study." Curr Ther Res Clin Exp 56 (1995): 1066-75</p><p id="ref_4">4. Tucker R, Denning D, Arathoon E, et al "Itraconazole therapy for nonmeningeal coccidioidomysosis: clinical and laboratory observations." J Am Acad Dermatol 23 (1990): 593-601</p><p id="ref_5">5. "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ. </p><p id="ref_6">6. Gupta AK,  Ryder JE "The use of oral antifungal agents to treat onychomycosis." Dermatol Clin 21 (2003): 469-79, vi</p><p id="ref_7">7. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_8">8. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_9">9. Piepponen T, Blomquist K, Brandt H, et al "Efficacy and safety of itraconazole in the long-term treatment of onychomycosis." J Antimicrob Chemother 29 (1992): 195-205</p><p id="ref_10">10. Tucker R, Haq Y, Denning D, Stevens D "Adverse events associated with itraconazole in 189 patients on chronic therapy." J Antimicrob Chemother 26 (1990): 561-6</p><p id="ref_11">11. Lavrijsen A, Balmus K, Nugteren-Huying W, et al "Hepatic injury associated with itraconazole." Lancet 340 (1992): 251-2</p><p id="ref_12">12. Chen J,  Song X,  Yang P,  Wang J "Appearance of anaphylactic shock after long-term intravenous itraconazole treatment." Ann Pharmacother 43 (2009): 537-41</p><p id="ref_13">13. Thompson GR 3rd,  Cadena J,  Patterson TF "Overview of antifungal agents." Clin Chest Med 30 (2009): 203-15, v</p><p id="ref_14">14. Debruyne D, Coquerel A "Pharmacokinetics of antifungal agents in onychomycoses." Clin Pharmacokinet 40 (2001): 441-72</p><p id="ref_15">15. Cleveland KO, Campbell JW "Hallucinations associated with itraconazole therapy." Clin Infect Dis 21 (1995): 456</p><p id="ref_16">16. "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ. </p><p id="ref_17">17. Gallardoquesada S, Luelmoaguilar J, Guanyabenscalvet C "Hepatotoxicity associated with itraconazole." Int J Dermatol 34 (1995): 589</p><p id="ref_18">18. "Itracanazole, terbinafine possibly linked to liver failure." Am J Health Syst Pharm 58 (2001): 1076</p><p id="ref_19">19. Ahmad SR, Singer SJ, Leissa BG "Congestive heart failure associated with itraconazole." Lancet 357 (2001): 1766-7</p><p id="ref_20">20. Gelfand MS,  Cleveland KO "Acute congestive heart failure and death secondary to itraconazole therapy." AIDS 26 (2012): 1848-50</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between Tolsura and Sporanox?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about itraconazole</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>38 Reviews</li>
<li>Drug class: azole antifungals</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Itraconazole &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Sporanox, Tolsura, Onmel</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Candida Urinary Tract Infection</li>
<li>Aspergillosis, Aspergilloma</li>
<li>Aspergillosis, Invasive</li>
<li>Blastomycosis</li>
<li data-more-config-id="list-data-resources-conditions">... +19 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to itraconazole: compounding powder, intravenous kit, oral capsule, oral solution, oral tablet</i></p><h3>General</h3><p>In clinical trials, side effects were reported in about 7% to 9% of patients receiving short-term therapy and about 15% of patients receiving prolonged (about 1 month) continuous therapy.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 11%), diarrhea (up to 11%)</p><p><b>Common</b> (1% to 10%): Vomiting, abdominal pain or discomfort, dyspepsia, flatulence, gingivitis, constipation, ulcerative stomatitis, gastritis, gastroenteritis</p><p><b>Rare</b> (less than 0.1%): Pancreatitis</p><p><b>Frequency not reported</b>: Dysphagia, hemorrhoids, gastrointestinal disorder<sup>[Ref]</sup></p><p>Pancreatitis, abdominal pain, vomiting, dyspepsia, nausea, diarrhea, and constipation have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypertriglyceridemia (up to 11%)</p><p><b>Common</b> (1% to 10%): Hypokalemia, increased blood alkaline phosphatase, hypomagnesemia, increased blood lactate dehydrogenase, hypophosphatemia, increased appetite</p><p><b>Uncommon</b> (0.1% to 1%): Fluid overload, hypocalcemia, anorexia, hyperglycemia</p><p><b>Frequency not reported</b>: Dehydration, decreased weight, hyperkalemia<sup>[Ref]</sup></p><p>Hypertriglyceridemia and hypokalemia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, hypoacusis, tremor, dysgeusia</p><p><b>Uncommon</b> (0.1% to 1%): Vertigo, somnolence, hypoesthesia, transient or permanent hearing loss, peripheral neuropathy</p><p><b>Rare</b> (less than 0.1%): Paresthesia, tinnitus<sup>[Ref]</sup></p><p>Peripheral neuropathy, paresthesia, hypoesthesia, headache, dizziness, tinnitus, transient or permanent hearing loss, dysgeusia, and tremor have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Rhinitis, upper respiratory tract infection, sinusitis, cough, pneumonia, increased sputum, dyspnea, pharyngitis, pulmonary infiltration</p><p><b>Uncommon</b> (0.1% to 1%): Pulmonary edema, pharyngolaryngeal pain</p><p><b>Frequency not reported</b>: Dysphonia<sup>[Ref]</sup></p><p>Pulmonary edema and dyspnea have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Other</h3><p>Edema and pyrexia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Pyrexia, injury, edema, chest pain, fatigue, malaise, pain, asthenia, Pneumocystis carinii infection, herpes zoster</p><p><b>Frequency not reported</b>: Unspecified infection, rigors, back pain, hot flushes, implantation complication, face edema, chills, generalized edema</p><p><b>Postmarketing reports</b>: Peripheral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus, hyperhidrosis, unspecified skin disorder, erythematous rash</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p><b>Rare</b> (less than 0.1%): Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, leukocytoclastic vasculitis, erythema multiforme, photosensitivity, alopecia<sup>[Ref]</sup></p><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, leukocytoclastic vasculitis, alopecia, photosensitivity, rash, pruritus, and urticaria have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Mild, transient elevations in liver function tests have occurred in 1% to 7% of patients receiving continuous therapy.</p><p></p><p>Serious hepatotoxicity (including some cases of fatal acute liver failure), hepatitis, and reversible increases in hepatic enzymes have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased hepatic enzymes (including reversible increases), bilirubinemia, abnormal liver function, increased ALT, jaundice, increased AST, increased GGT, hepatitis, hyperbilirubinemia</p><p><b>Rare</b> (less than 0.1%): Serious hepatotoxicity (including some cases of fatal acute liver failure)</p><p><b>Frequency not reported</b>: Cholestasis, cholestatic jaundice, hepatic failure<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, vein disorder, abnormal electrocardiogram</p><p><b>Uncommon</b> (0.1% to 1%): Hypotension, orthostatic hypotension, vasculitis, sinus bradycardia, tachycardia</p><p><b>Rare</b> (less than 0.1%): Congestive heart failure</p><p><b>Frequency not reported</b>: Premature ventricular contractions, cardiac failure, left ventricular failure<sup>[Ref]</sup></p><p>Congestive heart failure has also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased serum creatinine</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal renal function, increased blood urea</p><p><b>Frequency not reported</b>: Renal impairment<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, anxiety, abnormal dreaming</p><p><b>Frequency not reported</b>: Insomnia, decreased libido, visual hallucinations, confusional state<sup>[Ref]</sup></p><p>An elderly patient experienced visual hallucinations, confusion, and weakness after receiving itraconazole.  The symptoms reappeared following accidental itraconazole doses 7 and 10 days later.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Pollakiuria, menstrual disorders, and erectile dysfunction have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Cystitis, urinary tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Impotence, menstrual disorders, abnormal urine analysis</p><p><b>Rare</b> (less than 0.1%): Pollakiuria, erectile dysfunction</p><p><b>Frequency not reported</b>: Albuminuria, hematuria, gynecomastia, male breast pain, bacteriuria</p><p><b>Postmarketing reports</b>: Urinary incontinence<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia, bursitis, back pain</p><p><b>Rare</b> (less than 0.1%): Increased blood creatine phosphokinase</p><p><b>Postmarketing reports</b>: Arthralgia<sup>[Ref]</sup></p><p>Increased blood creatine phosphokinase and myalgia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Local</h3><p>IV:</p><p><b>Common</b> (1% to 10%): Application site reaction</p><p><b>Frequency not reported</b>: Injection site inflammation<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>At least 1 case of anaphylactic shock after long-term IV therapy has been reported.</p><p></p><p>Anaphylactic reactions, allergic reactions, serum sickness, and angioneurotic edema have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Rare</b> (less than 0.1%): Allergic reactions (e.g., pruritus, rash, urticaria, angioedema), serum sickness, angioneurotic edema, anaphylactic reaction</p><p><b>Frequency not reported</b>: Anaphylactic shock</p><p><b>Postmarketing reports</b>: Anaphylaxis, anaphylactoid reaction<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Visual disturbances (including blurred vision, diplopia)</p><p><b>Frequency not reported</b>: Abnormal vision<sup>[Ref]</sup></p><p>Visual disturbances (including blurred vision, diplopia) have also been reported during postmarketing experience.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Leukopenia has also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Rare</b> (less than 0.1%): Leukopenia</p><p><b>Frequency not reported</b>: Granulocytopenia</p><p><b>Postmarketing reports</b>: Neutropenia, thrombocytopenia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Adrenal insufficiency<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Sporanox injection (itraconazole)" Ortho Biotech Inc, Raritan, NJ. </p><p id="ref_2">2. Haria M, Bryson HM, Goa KL "Itraconazole: a review of its pharmacological properties and therapeutic use in the management of superficial fungal infections." Drugs 52 (1996): 253</p><p id="ref_3">3. Kim JA, Ahn KJ, Kim JM, Youn JI "Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study." Curr Ther Res Clin Exp 56 (1995): 1066-75</p><p id="ref_4">4. Tucker R, Denning D, Arathoon E, et al "Itraconazole therapy for nonmeningeal coccidioidomysosis: clinical and laboratory observations." J Am Acad Dermatol 23 (1990): 593-601</p><p id="ref_5">5. "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ. </p><p id="ref_6">6. Gupta AK,  Ryder JE "The use of oral antifungal agents to treat onychomycosis." Dermatol Clin 21 (2003): 469-79, vi</p><p id="ref_7">7. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_8">8. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_9">9. Piepponen T, Blomquist K, Brandt H, et al "Efficacy and safety of itraconazole in the long-term treatment of onychomycosis." J Antimicrob Chemother 29 (1992): 195-205</p><p id="ref_10">10. Tucker R, Haq Y, Denning D, Stevens D "Adverse events associated with itraconazole in 189 patients on chronic therapy." J Antimicrob Chemother 26 (1990): 561-6</p><p id="ref_11">11. Lavrijsen A, Balmus K, Nugteren-Huying W, et al "Hepatic injury associated with itraconazole." Lancet 340 (1992): 251-2</p><p id="ref_12">12. Chen J,  Song X,  Yang P,  Wang J "Appearance of anaphylactic shock after long-term intravenous itraconazole treatment." Ann Pharmacother 43 (2009): 537-41</p><p id="ref_13">13. Thompson GR 3rd,  Cadena J,  Patterson TF "Overview of antifungal agents." Clin Chest Med 30 (2009): 203-15, v</p><p id="ref_14">14. Debruyne D, Coquerel A "Pharmacokinetics of antifungal agents in onychomycoses." Clin Pharmacokinet 40 (2001): 441-72</p><p id="ref_15">15. Cleveland KO, Campbell JW "Hallucinations associated with itraconazole therapy." Clin Infect Dis 21 (1995): 456</p><p id="ref_16">16. "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ. </p><p id="ref_17">17. Gallardoquesada S, Luelmoaguilar J, Guanyabenscalvet C "Hepatotoxicity associated with itraconazole." Int J Dermatol 34 (1995): 589</p><p id="ref_18">18. "Itracanazole, terbinafine possibly linked to liver failure." Am J Health Syst Pharm 58 (2001): 1076</p><p id="ref_19">19. Ahmad SR, Singer SJ, Leissa BG "Congestive heart failure associated with itraconazole." Lancet 357 (2001): 1766-7</p><p id="ref_20">20. Gelfand MS,  Cleveland KO "Acute congestive heart failure and death secondary to itraconazole therapy." AIDS 26 (2012): 1848-50</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between Tolsura and Sporanox?</li>
</ul><h2>More about itraconazole</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>38 Reviews</li>
<li>Drug class: azole antifungals</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Itraconazole &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Candida Urinary Tract Infection</li>
<li>Aspergillosis, Aspergilloma</li>
<li>Aspergillosis, Invasive</li>
<li>Blastomycosis</li>
<li data-more-config-id="list-data-resources-conditions">... +19 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>